AIM ImmunoTech
Develops Ampligen as an immunotherapy adjunct for metastatic pancreatic cancer.
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039
OCALA, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the United States Patent and Trademark Office has granted a patent covering the use of the Company's drug Ampligen in combination with the PD-1 checkpoint inhibitor pembrolizumab for the treatment of cancer.
Metals One partner rejects claim that Barbrook mine deal has failed
Lions Bay Resources has rejected a claim by Vantage Goldfields that its proposed acquisition of the Barbrook gold mine in South Africa has failed, describing the statement as false and misleading. The company is owned by Metals One PLC (AIM:MET1, FRA:HT7, OTCQB:MTOPF), the AIM-listed mining company, and Lions Bay Capital, which trades on the TSX Venture Exchange.
Alien Metals shares rise 4% after bonanza-grade silver results
Shares in Alien Metals Ltd (AIM:UFO, OTC:ASLRF), the AIM-listed minerals exploration and development company, rose 4% to 0.10p on Thursday. The move followed diamond drilling results from the Elizabeth Hill Silver Project in Western Australia, announced by joint venture partner West Coast Silver, which is listed on the Australian Securities Exchange.
Thruvision shares rise over 14% after Canadian government order
Shares in Thruvision Group PLC (AIM:THRU, OTC:DIGTF), the walk-through security screening company listed on AIM, rose 14% to 1.40p on Thursday. The move followed news of a new order in Canada, marking Thruvision's first government customer in the country and its first deployment in Canada's entrance security market.
Tower Resources tops up working capital as farm-out moves closer to completion
Tower Resources PLC (AIM:TRP, FRA:ULF1) has raised £325,000 of additional working capital as it moves closer to completing farm-out transactions in Namibia and Cameroon that are expected to unlock further funding. The AIM-listed group issued around 2.36 billion shares at 0.01375p each, an approximately 8% discount to Friday's closing bid price.
Cavendish lifts Optima Health target as annual profit beats forecasts
Cavendish raised its price target on Optima Health PLC (AIM:OPT, OTC:OHLTF, FRA:J3N), the occupational health provider, after full-year profit came in ahead of the broker's forecasts and it signalled growing confidence in the company's medium-term targets. The AIM-listed group reported adjusted earnings before interest, tax, depreciation and amortisation of £20.1 million for the year to March, around 12% above Cavendish's estimate and roughly 10% ahead of wider market expectations.
Moog Celebrates 75 Years of Innovation with New Advanced Integrated Manufacturing Facility, Workforce Investment and STEM Scholarship Initiative
Moog Inc. (NYSE: MOG.A and MOG.B) today celebrated the opening of its new Advanced Integrated Manufacturing (AIM) facility while marking the company's 75th anni
AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense' Article
Article by CEO Thomas K. Equels calls for proactive evaluation of broad-spectrum antiviral countermeasures before novel viral threats emerge
Bravura Solutions shares climb as AIM newbie marks 76% jump in cash earnings
Bravura Solutions Ltd (AIM:BVS), the wealth management software firm that floated last month, got off to a positive start on Wednesday after reporting a 76% jump in underlying cash EBITDA to A$77.1 million for FY26 and unveiled an on-market share buyback of up to A$50 million, alongside A$67.3 million of final and special dividends. Underlying revenue increased 9.6% to A$282.6 million despite second-half currency headwinds, while recurring revenue rose 6.9% to A$165.0 million.
Thruvision shares surge 46% to 0.91p on £3m Asian airport contract
Thruvision Group PLC (AIM:THRU, OTC:DIGTF) shares jumped 46% to 0.91p after the security screening group landed its largest contract in Asia to date. The AIM-listed company said its principal regional partner has won a deal to deploy Thruvision systems across several major airports in South-East Asia, generating more than £3 million of revenue.
Major boon predicted for Jersey Oil & Gas as bullish broker repeats Buy rating
Cavendish sees almost fivefold upside in Jersey Oil and Gas PLC (AIM:JOG, OTC:JYOGF) after regulators extended the Verbier licence, giving the partners more time to advance an integrated Greater Buchan Area development. The broker has repeated a Buy recommendation and 537p price target, representing 388% upside from the AIM-listed company's 110p share price.
AIM ImmunoTech Ahead of Schedule on ‘Last Dose' DURIPANC Critical Clinical Inflection Point
Milestone Advances Ampligen® Toward Key Clinical Benefit Readout in December 2026 and Overall Survival Analysis in Mid-2027 Milestone Advances Ampligen® Toward Key Clinical Benefit Readout in December 2026 and Overall Survival Analysis in Mid-2027
Admission to Trading on the Main Market and AIM Cancellation
Reykjavík, July 31, 2026 (GLOBE NEWSWIRE) -- THIS ANNOUNCEMENT IS MADE FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE COMMON SHARES IN AMAROQ LTD. IN ANY JURISDICTION.
Cavendish sees 18-fold upside at 88 Energy on Alaska prospect scale
Cavendish has reiterated its buy rating and 19.8p target price on 88 Energy Ltd (AIM:88E, ASX:88E, OTCQB:EEENF, FRA:POQ), implying significant untapped upside from the current 1.02p share price. The AIM-listed oil and gas explorer's South Prudhoe acreage on Alaska's North Slope now holds 768.9 million barrels of gross prospective resources, of which 640.7 million barrels are net to the company.
Seeing Machines wins European carmaker deal as EU driver monitoring rules come into force
Seeing Machines Ltd (AIM:SEE, OTC:SEEMF, FRA:M2Z), the AIM-listed computer vision company, has secured a new driver and occupant monitoring contract with a European carmaker as fresh European Union safety rules take effect. The award, won through an existing Tier 1 supplier, is expected to generate around $5 million in lifetime revenue.
CelLBxHealth builds £3.5m weighted pipeline as revenue growth target held
CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the AIM-listed cancer diagnostics company, said its commercially weighted pipeline had built to £3.5 million, supported by rising engagement from pharmaceutical and diagnostic partners. It reiterated its forecast for revenue of at least £2.1 million for the 2026 financial year, growth of at least 50% on the prior year.
AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program
Access it here OCALA, Fla. , July 07, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced the release of its latest CEO Corner segment, featuring Chief Executive Officer Thomas Equels discussing the Company's continued momentum in pancreatic cancer and the significant clinical, strategic and operational milestones positioning Ampligen for its next stage of development.
AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program
CEO Thomas Equels discusses recent clinical progress, upcoming milestones and the Company's commitment to advancing Ampligen® for patients with pancreatic cancer CEO Thomas Equels discusses recent clinical progress, upcoming milestones and the Company's commitment to advancing Ampligen® for patients with pancreatic cancer
Coiled Therapeutics develops improved formulation of experimental cancer drug ahead of trial expansion
Coiled Therapeutics (AIM:COIL, OTCQB:COTXF), a clinical-stage oncology company developing medicines for hard-to-treat cancers, has created a new oral formulation of its lead drug candidate designed to improve how the treatment is absorbed by the body. The AIM-listed company said it expects to dose the first patient with the reformulated version of AO-252 this month.
Phoenix Copper shares drop on discount equity raise
Phoenix Copper Ltd (AIM:PXC, OTCQX:PXCLF, FRA:5HR) said it plans to raise around £2.3 million through a placing and subscription at a steep discount, while warning that further funding will still be needed before the end of September. The AIM-listed Idaho copper developer is proposing to issue around 460 million new shares at 0.5p each, a 54.5% discount to the 1.1p closing mid-market price on 2 July.